Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease

被引:0
|
作者
Pandey, Akancha [1 ,5 ]
Raja, Rubesh [1 ]
Estepp, Jeremie H. [2 ,3 ,6 ]
Ramkrishna, Doraiswami [1 ,4 ]
机构
[1] Purdue Univ, Davidson Sch Chem Engn, W Lafayette, IN USA
[2] St Jude Childrens Res Hosp, Dept Hematol, Memphis, TN USA
[3] St Jude Childrens Res Hosp, Dept Global Pediat Med, Memphis, TN USA
[4] Purdue Univ, Davidson Sch Chem Engn, 480 Stadium Mall Dr, W Lafayette, IN 47907 USA
[5] AbbVie Inc, South San Francisco, CA USA
[6] Agios Pharmaceut, Cambridge, MA USA
来源
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY | 2023年 / 12卷 / 06期
关键词
ADHERENCE RATE THRESHOLD; QUALITY-OF-LIFE; ALTERNATE-DAY; ANEMIA; CHILDREN; HYDROXYCARBAMIDE; NONCOMPLIANCE; ATORVASTATIN; MULTICENTER; MORBIDITY;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nonadherence is common in individuals with sickle cell disease (SCD) on hydroxyurea therapy and can be observed with waning improvements in hematologic parameters or biomarkers like mean cell volume and fetal hemoglobin level over time. We modeled the impact of hydroxyurea nonadherence on longitudinal biomarker profiles. We estimated the potential nonadherent days in individuals exhibiting a drop in biomarker levels by modifying the dosing profile using a probabilistic approach. Incorporating additional nonadherence using our approach besides existing ones in the dosing profile improves the model fits. We also studied how different patterns in adherence give rise to various physiological profiles of biomarkers. The key finding is consecutive days of nonadherence are less favorable than when nonadherence is interspersed. These findings improve our understanding of nonadherence and how appropriate intervention strategies can be applied for individuals with SCD susceptible to the severe impacts of nonadherence.
引用
收藏
页码:748 / 757
页数:10
相关论文
共 50 条
  • [31] Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease
    Candrilli, Sean D.
    O'Brien, Sarah H.
    Ware, Russell E.
    Nahata, Milap C.
    Seiber, Eric E.
    Balkrishnan, Rajesh
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (03) : 273 - 277
  • [32] Hydroxyurea therapy in sickle cell disease: An alternative approach to preoperative red cell transfusion
    Okoye, Nneka C.
    Meier, Emily R.
    Darbari, Deepika S.
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2015, 107 (02) : 102 - 103
  • [33] Hydroxyurea is associated with later onset of acute splenic sequestration crisis in sickle cell disease: Lessons from the European Sickle Cell Disease Cohort-Hydroxyurea (ESCORT-HU) study
    Allali, Slimane
    Galacteros, Frederic
    Oevermann, Lena
    Cannas, Giovanna
    Joseph, Laure
    Loko, Gylna
    Elenga, Narcisse
    Benkerrou, Malika
    Etienne-Julan, Maryse
    Castex, Marie-Pierre
    Brousse, Valentine
    de Montalembert, Mariane
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (04) : 555 - 561
  • [34] Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study
    de Montalembert, Mariane
    Voskaridou, Ersi
    Oevermann, Lena
    Cannas, Giovanna
    Habibi, Anoosha
    Loko, Gylna
    Joseph, Laure
    Colombatti, Raffaella
    Bartolucci, Pablo
    Brousse, Valentine
    Galacteros, Frederic
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (10) : 1223 - 1231
  • [35] Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease
    Badawy, Sherif M.
    Thompson, Alexis A.
    Holl, Jane L.
    Penedo, Frank J.
    Liem, Robert I.
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2018, 35 (5-6) : 297 - 308
  • [36] Hydroxyurea and arginine therapy: Impact on nitric oxide production in sickle cell disease
    Morris, CR
    Vichinsky, EP
    van Warmerdam, J
    Machado, L
    Kepka-Lenhart, D
    Morris, SM
    Kuypers, FA
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (08) : 629 - 634
  • [37] Genetic Modifiers of HbF and Response to Hydroxyurea in Sickle Cell Disease
    Green, Nancy S.
    Barral, Sandra
    PEDIATRIC BLOOD & CANCER, 2011, 56 (02) : 177 - 181
  • [38] Plasma immune mediators as laboratorial biomarkers for Sickle Cell Disease patients according to the hydroxyurea therapy and disease severity
    de Oliveira Toledo, Silvia Leticia
    Ladeira, Valeria Sutana
    Nogueira, Leilismara Sousa
    Resende Ferreira, Leticia Goncalves
    Oliveira, Marina Mendes
    Reno, Cristiane de Oliveira
    dos Santos, Herica Lima
    Alves Coelho-dos-Reis, Jordana Grazziela
    Campi-Azevedo, Ana Carolina
    Teixeira-Carvalho, Andrea
    Martins-Filho, Olindo Assis
    Alves Rios, Danyelle Romana
    Barros-Pinheiro, Melina
    BLOOD CELLS MOLECULES AND DISEASES, 2023, 98
  • [39] Hydroxyurea in Sickle Cell Disease: Our Experience in Western India
    Deshpande, S. V.
    Bhatwadekar, S. S.
    Desai, Parth
    Bhavsar, Tarang
    Patel, Ankit
    Koranne, Amey
    Mehta, Arpan
    Khadse, Shweta
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2016, 32 (02) : 215 - 220
  • [40] Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease
    Rodriguez, Anar
    Duez, Pierre
    Dedeken, Laurence
    Cotton, Frederic
    Ferster, Alina
    PEDIATRIC BLOOD & CANCER, 2018, 65 (07)